Gynecologic Oncology

Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study.  163:85-92. 2021

Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.  162:532-538. 2021

It's time to re-evaluate cervical Cancer screening after age 65.  162:200-202. 2021

Understanding the effect of mechanical forces on ovarian cancer progression.  162:154-162. 2021

Erratum to “A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States” (Gynecologic Oncology (2020) 159(2) (344–353), (S0090825820338506), (10.1016/j.ygyno.2020.08.033)).  161:913. 2021

Standing on the shoulders of giants: Mentorship advice from leaders in the field.  161:339-341. 2021

Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.  161:496-501. 2021

Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.  160:817-826. 2021

Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II.  160:827-834. 2021

The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?.  160:800-804. 2021

Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.  160:793-799. 2021

Corrigendum to ʻA state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States’ [Gynecologic Oncology 159 (2020) 344–353] (Gynecologic Oncology (2020) 159(2) (344–353), (S0090825820338506), (10.1016/j.ygyno.2020.08.033)) 2021

Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.  160:285-294. 2021

Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm.  159:773-777. 2020

A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States.  159:344-353. 2020

51st Annual Meeting of the Society of Gynecologic Oncology.  159:1. 2020

Corrigendum to ‘Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer’ [Gynecologic Oncology 157 (2020) 765–774] (Gynecologic Oncology (2020) 157(3) (765–774), (S0090825820302262), (10.1016/j.ygyno.2020.03.010)).  159:295. 2020

Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.  158:562-569. 2020

Risk of second primary cancers among survivors of gynecological cancers.  158:719-726. 2020

Human papillomavirus: The other invisible enemy.  158:254-255. 2020

When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic.  158:236-243. 2020

Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.  158:16-24. 2020

Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).  158:123-129. 2020

Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II.  158:201-207. 2020

Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I.  158:194-200. 2020

Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.  157:578-584. 2020

Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.  157:765-774. 2020

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).  157:161-166. 2020

The Society of Gynecologic Oncology wellness curriculum pilot: A groundbreaking initiative for fellowship training.  156:710-714. 2020

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.  156:301-307. 2020

Extensive financial hardship among gynecologic cancer patients starting a new line of therapy.  156:271-277. 2020

Human papillomavirus vaccination: Ongoing challenges and future directions.  156:498-502. 2020

Reducing emergency department (ED) computed tomography (CT) utilization in women treated for gynecologic cancers.  156:288-292. 2020

The financial impact of an enhanced recovery after surgery (ERAS) protocol in an academic gynecologic oncology practice.  156:284-287. 2020

Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models 2020

Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation.  155:365-373. 2019

Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.  155:201-206. 2019

Corrigendum to “Financial toxicity – An overlooked side effect” (Gynecologic Oncology (2018) 150(1) (3–6), (S0090825818308990), (10.1016/j.ygyno.2018.05.012)).  154:449. 2019

Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.  154:379-382. 2019

Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.  154:110-117. 2019

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.  153:521-529. 2019

Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution.  153:242-247. 2019

Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.  153:381-384. 2019

Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.  152:445-451. 2019

The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.  152:127-132. 2019

Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center..  151:501-505. 2018

Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy.  151:282-286. 2018

Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer..  151:4-5. 2018

Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman.  151:6-9. 2018

Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey.  150:494-500. 2018

Endometrial cancer: Molecular markers and management of advanced stage disease.  150:569-580. 2018

Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years.  150:391-397. 2018

Financial toxicity – An overlooked side effect.  150:3-6. 2018

Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication.  149:506-512. 2018

Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.  149:525-530. 2018

Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.  149:337-340. 2018

Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?.  149:49-52. 2018

HPV vaccination.  148:3-4. 2018

Values and worries of ovarian cancer patients.  147:433-438. 2017

Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.  147:98-103. 2017

The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis.  146:642-646. 2017

A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.  145:291-297. 2017

Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort.  144:274-278. 2017

Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?.  144:125-129. 2017

Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial.  144:193-199. 2017

Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service.  143:105-108. 2016

Ovarian cancer and the immune system — The role of targeted therapies.  142:349-356. 2016

Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.  142:25-29. 2016

A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results.  141:364-370. 2016

A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3).  140:245-252. 2016

Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?.  143:617-621. 2016

Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.  143:674-683. 2016

The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study.  140:264-269. 2016

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.  139:413-418. 2015

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis.  139:59-62. 2015

Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.  138:656-662. 2015

Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center..  138:689-693. 2015

A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.  136:293-299. 2015

Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance.  136:178-182. 2015

Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?.  136:43-47. 2015

Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian cancers: An observational study ancillary analysis.  138:267-271. 2015

Ovarian and cervical cancer patient derived xenografts: The past, present, and future.  138:486-491. 2015

Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial.  137:47-54. 2015

Functional variants in CYP1A1 and GSTM1 are associated with clearance of cervical HPV infection.  135:560-564. 2014

Teaching gynecologic oncology in Low resource settings: A collaboration of health volunteers overseas and the society of gynecologic oncology.  135:580-582. 2014

Diabetes mellitus and ovarian cancer: More complex than just increasing risk.  135:273-277. 2014

Abnormal CA-125 levels in menopausal women without ovarian cancer.  135:34-37. 2014

Validation of a venous thromboembolism risk assessment model in gynecologic oncology..  134:160-163. 2014

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study.  133:433-438. 2014

A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.  132:531-536. 2014

An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.  134:331-337. 2014

Black race independently predicts worse survival in uterine carcinosarcoma.  133:238-241. 2014

Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients.  132:227-230. 2014

Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer.  134:112-120. 2014

Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.  132:203-210. 2014

Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma.  133:234-237. 2014

Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.  133:142-146. 2014

Reducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care..  131:508-511. 2013

The Wnt/β-catenin pathway in ovarian cancer: A review.  131:772-779. 2013

Erratum: HPV vaccination in women treated for CIN2/3: It's still all about prevention (Gynecologic Oncology (2013) 130 (255-256)).  131:499. 2013

Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.  131:493-498. 2013

A phase i clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.  130:518-524. 2013

Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer.  130:421-425. 2013

Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis.  130:416-420. 2013

Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?.  130:317-322. 2013

HPV vaccination in women treated for CIN2/3: It's still all about prevention.  130:255-256. 2013

Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins.  129:528-532. 2013

Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trials.  129:251-257. 2013

Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors.  131:59-62. 2013

Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.  131:158-162. 2013

Re: "The utilization of palliative care in gynecologic oncology patients near the end of life"..  127:678-679. 2012

A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.  127:420-425. 2012

Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.  127:267-272. 2012

The utilization of palliative care in gynecologic oncology patients near the end of life..  127:175-179. 2012

Management of complex pelvic masses using a multivariate index assay: A decision analysis.  126:364-368. 2012

Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy.  126:69-72. 2012

Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusion.  125:646-648. 2012

The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.  125:226-230. 2012

Does economic burden influence quality of life in breast cancer survivors?.  124:437-443. 2012

Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells.  124:598-605. 2012

Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: A pilot study.  123:360-364. 2011

Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies.  123:54-57. 2011

A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma.  122:604-607. 2011

Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.  122:532-535. 2011

Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines.  122:396-401. 2011

Erratum: Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions (Gynecologic Oncology (2010) 118 (274-277)).  121:643. 2011

Multiple synchronous primary ovarian malignancies in a patient with a MLH-1 mutation: Impact on potential fertility preservation.  121:637-638. 2011

Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.  121:193-199. 2011

Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence.  122:501-504. 2011

Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.  119:237-242. 2010

Long-term outcome and natural history of uterine adenosarcomas.  119:305-308. 2010

Overcoming TRAIL resistance in ovarian carcinoma.  119:157-163. 2010

Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions.  118:274-277. 2010

Evaluation of EVI1 and EVI1s (Δ324) as potential therapeutic targets in ovarian cancer.  118:189-195. 2010

Overcoming the barriers to HPV vaccination in high-risk populations in the US.  117:486-490. 2010

What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?.  117:481-485. 2010

Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.  117:248-254. 2010

Epithelioid trophoblastic tumor masquerading as invasive squamous cell carcinoma of the cervix after an ectopic pregnancy.  117:387-388. 2010

How does public policy impact cervical screening and vaccination strategies?.  119:175-180. 2010

Extragenital adenosarcoma: A case report, review of the literature, and management discussion.  115:472-475. 2009

An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).  115:244-248. 2009

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study..  114:424-426. 2009

The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.  114:242-245. 2009

Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.  113:384-390. 2009

Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.  112:558-562. 2009

The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies..  112:601-604. 2009

The effect of obesity on survival in patients with ovarian cancer.  112:389-393. 2009

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.  111:89-94. 2008

Corrigendum to "The current and future role of screening in the era of HPV vaccination" [Gynecol. Oncol. 109 (2008) S31-S39] (DOI:10.1016/j.ygyno.2008.02.001).  110:270. 2008

Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer.  110:268-269. 2008

Age considerations when vaccinating against HPV.  109. 2008

Initial lessons learned in HPV vaccination.  109. 2008

The disparity of cervical cancer in diverse populations.  109. 2008

The future of vaccines for cervical cancer.  109. 2008

Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.  108:591-597. 2008

Oncolytic adenovirus Ad5/3-Δ24 and chemotherapy for treatment of orthotopic ovarian cancer.  108:166-172. 2008

The current and future role of screening in the era of HPV vaccination.  109. 2008

Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.  107:398-403. 2007

Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms.  106:622-625. 2007

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.  106:614-621. 2007

Complete uterine necrosis following chemoradiation for advanced cervical cancer: a case report..  106:265-267. 2007

A multi-institutional review of outcomes of endometrial stromal sarcoma.  105:630-634. 2007

Fertility-sparing radical abdominal trachelectomy for clear cell adenocarcinoma of the upper vagina: A case report.  105:820-822. 2007

Anemia correction in malignancy management: Threat or opportunity?.  105:517-529. 2007

Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.  105:291-298. 2007

A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.  105:223-227. 2007

A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.  104:591-595. 2007

Primary appendiceal cancer: Gynecologic manifestations and treatment options.  104:602-606. 2007

Fertility sparing therapy in a patient with placental site trophoblastic tumor: A case report.  103:1141-1143. 2006

Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision.  103:749-751. 2006

Unilateral cervical cancer in a patient with cervix duplex.  103:346-348. 2006

Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.  102:338-342. 2006

Recurrent basosquamous cell carcinoma of the vulva.  102:400-402. 2006

Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.  101:46-54. 2006

Carcinosarcoma of the ovary - A case series.  100:128-132. 2006

Re: "outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy" [2] (multiple letters).  100:219-220. 2006

Optical detection of cervical neoplasia: results from an internally-controlled multicenter study..  99:S53. 2005

The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).  99:557-563. 2005

The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: A patient care evaluation study from the American College of Surgeons National Cancer Data Base.  99:530-535. 2005

A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses.  99:443-446. 2005

Predictors of outcomes for women with cervical carcinoma.  99:432-436. 2005

Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: Initial examination of celecoxib as a chemopreventive agent.  98:376-382. 2005

Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies..  98:490-492. 2005

Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report.  98:155-157. 2005

Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery.  96:341-348. 2005

Immune responses to human papillomavirus in genital tract of women with cervical cancer.  96:452-461. 2005

A case report of rhabdomyosarcoma of the uterus associated with uterine inversion.  96:850-853. 2005

Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis.  97:387-394. 2005

Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy.  97:713-715. 2005

Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy.  98:309-312. 2005

The impact of aborted radical hysterectomy in patients with cervical carcinoma.  95:204-207. 2004

Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma.  94:352-362. 2004

Primary lung large cell carcinoma metastatic to the vulva: A case report and review of the literature.  94:829-831. 2004

Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.  93:429-434. 2004

The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy.  92:215-219. 2004

Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: A preliminary investigation.  89:233-235. 2003

Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy.  89:295-300. 2003

Complications of indwelling venous access devices in patients with gynecologic malignancies.  91:591-595. 2003

Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.  91:470-475. 2003

A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis.  87:57-63. 2002

Conservative management of Stage I endometrial carcinoma after surgical staging.  84:194-200. 2002

Treatment preferences in recurrent ovarian cancer.  86:200-211. 2002

A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts.  83:432-438. 2001

An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites.  82:57-63. 2001

Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix.  83:370-377. 2001

Genetic origin of malignant trophoblastic neoplasms analyzed by sequence tag site polymorphic markers.  81:247-253. 2001

Immunohistochemical expression of molecular markers in an avian model: A potential model for preclinical evaluation of agents for ovarian cancer chemoprevention.  81:373-379. 2001

Predictors of outcome in small cell carcinoma of the cervix - A case series.  83:216-220. 2001

Transcriptional targeting for ovarian cancer gene therapy.  82:229-237. 2001

A patient presenting with a pelvic mass, elevated CA-125, and fever.  77:471-472. 2000

An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches.  74:227-234. 1999

High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type I vector.  71:278-287. 1998

An umbilical metastasis after laparoscopy for squamous cell carcinoma of the cervix.  64:507-509. 1997

Intraperitoneal radioimmunotherapy of ovarian cancer with ¹⁷⁷Lu- CC49: A phase I/II study.  65:94-101. 1997

Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy.  64:378-385. 1997

Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbb-2 single-chain antibody.  59:8-14. 1995

Intracranial metastases from carcinoma cervix and review of literature.  46:391-392. 1992

Coexisting intraductal breast carcinoma and metastatic choriocarcinoma presenting as a breast mass.  43:295-299. 1991

Establishment and characterization of a human cell line from a serous papillary endometrial carcinoma.  33:301-312. 1989

Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits.  32:314-318. 1989

Endometrial stromal cells in culture: An attempt to understand the genesis and biologic activity of uterine sarcomas.  24:247-257. 1986

Genital aerobic bacterial flora of women receiving radiotherapy for gynecologic malignancy.  23:35-39. 1986

An extra-adrenal pheochromocytoma mimicking lymph node metastasis from a cervical cancer.  13:416-422. 1982